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Glucose: the worst of all evils?
Introduction
Hyperglycaemia is common in critically ill patients.1,2,3,4,5 The acute 
phase response is associated with the abundant production of pro- 
and anti-inflammatory mediators and counterregulatory hormones, 
causing pathologic metabolic derangements.6,7 Hyperglycaemia 
occurs secondary to elevated levels of cortisol, epinephrine, 
norepinephrine, glucagon resulting in gluconeogenesis and 
glycogenolysis, as well as insulin resistance.5,6 
Hyperglycaemia may cause harm through a direct toxic effect, 
increased intracellular oxidative stress due to higher mitochondrial 
peroxide production,5 altered cytokine production and impaired 
phagocytosis.6 Hyperglycaemia is a marker of severity of illness, and 
is associated with adverse outcomes, including increased morbidity 
and mortality in various patient populations.2,3,5,6,8,9 The adverse 
consequences include increased infectious complications and higher 
mortality in trauma patients,10,11,12 worse neurological outcome in 
a subset of traumatic brain injury (TBI) patients,13 poor functional 
recovery and higher mortality in stroke patients,14,15,16,17 and an 
increased morbidity and mortality after myocardial infarction18,19 as 
well as higher morbidity and mortality in other critically ill patients.20,21 
In addition, hyperglycaemia during critical illness is associated with 
worse long-term outcomes such as degree of disability after a 
stroke14 and risk for mortality and congestive heart failure one year 
after a myocardial infarction.23
The obvious question thus is: will intensive insulin therapy (IIT) 
improve morbidity and mortality in critically ill patients?
The past
When the first randomised clinical trials on blood glucose control in 
critically ill patients were first reported in 1995,23 physicians did not 
place a high priority on blood glucose (BG) control.23 Hyperglycaemia 
was considered part of the usual clinical course of critical illness 
and often not treated until levels exceeded the renal threshold of 
12 mmol/L when it induced glucosuria and hypovolaemia.24 Insulin 
was administered according to a sliding scale and few protocols 
tried to match insulin dose to nutritional intake and the effectiveness 
of these protocols were not assessed.23
Tight glucose control
One of the first randomised clinical trials on Tight Glucose Control 
(TGC), utilising intravenous insulin followed by multiple dose insulin 
therapy, was the Diabetes Insulin-Glucose in Acute Myocardial 
Infarction (DIGAMI) study. Mortality at one year was reduced by 
26%.22 It is, however, unclear whether this outcome was due to tight 
control during hospitalisation or due to better diabetes management 
after discharge.1 The multicentre DIGAMI 2 trial could not reproduce 
these results and found no effect on morbidity or mortality after two 
years of follow up, possibly due to an inability to recruit an adequate 
number of patients25,1 and the inability to achieve strict control.26
The landmark study by Van Den Berghe, et al (Leuven 1) was the 
first large randomised trial in critically ill patients in a surgical 
intensive care unit (SICU) (mainly coronary bypass surgery, 13% 
with diabetes) with hyperglycaemia and included both diabetic and 
non-diabetic patients.27 Aggressive control, (BG 4.5–6.0 mmol/L) 
was associated with a significant reduction in ventilator support and 
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renal replacement therapy with a significant cost saving. The ICU 
mortality rate was reduced from 8% in the control group to 4.6% 
in the TGC group, and similarly, in-hospital mortality was reduced 
from 10.9% to 7.2%. The relative risk of in-hospital death was thus 
reduced by 33.9%. The benefit occurred in patients who remained in 
the ICU for > 5 days. The number of deaths in the first five days was 
similar in both groups.27 
The results were very different when the same authors proceeded to 
apply the same protocol to medical ICU patients (MICU) (Leuven 2).28 
The mortality rate was lower in patients who stayed in ICU for ≥ 3 
days, but higher in those that stayed < 3 days. The mortality reduction 
in the group who stayed longer in ICU was much smaller (6%) than 
the 42% reduction seen in the surgical ICU study.28 From these two 
studies it seems that the beneficial effect was more pronounced in 
severely ill patients requiring prolonged ICU care.5
These studies led to the publication of guidelines for the management 
of severe sepsis and shock which recommended TGC as an important 
part of management29 and was again included in the updated version 
of the guidelines in 2008.30 It is surprising that TGC was widely 
adopted after the Leuven 1 study, since the authors stated that their 
patients were: 1) ventilated surgical patients, 2) admitted to ICU after 
predominantly cardiac surgery and 3) that the results can not be 
extrapolated to other groups of ICU patients. The Volume Substitution 
and Insulin Therapy in Severe Sepsis (VISEP) trial applied the same 
protocol to septic patients and achieved lower BG concentrations, 
but no decrease in mortality.31 Two studies did not find a decrease in 
mortality with TGC in mixed ICU populations.3,32 
A large multi-centre trial, the NICE-SUGAR trial, compared patients 
whose blood glucose concentrations were maintained below 
6.7 mmol/L (TGC) with those whose blood glucose was kept between 
7.8–10.0 mmol/L in MICU and SICU patients in 42 hospitals. Although 
lower BG concentrations were achieved, TGC did not improve 
outcomes in terms of length of stay (LOS) in ICU or hospital, median 
number of days on mechanical ventilation or renal replacement 
therapy. Hypoglycaemia was recorded in 6.8% of the TGC group 
and 0.5% in the control group. Mortality was significantly higher in 
patients with tight control (27.5%–24.9%).2 
Two recent meta-analyses have also evaluated TCG. The first one 
(done prior to the NICE-SUGAR study) found a significant decreased 
incidence in sepsis (subgroup analysis suggests that it was limited 
to SICU patients), no association with new need for dialysis, an 
increased risk for hypoglycaemia and no impact on mortality.33 The 
second meta-analysis included the results from the NICE-SUGAR 
study confirmed these findings with regards to hypoglycaermia, but 
suggested that there is a mortality benefit with TGC surgical ICU 
patients.9
Methodological differences
The different outcomes between the Leuven 127 and the VISEP31 trials 
were probably due to differences in design and study population. 
The VISEP trial was designed as a four arm study comparing two 
resuscitation fluids (10% pentastarch versus modified Ringer’s 
lactate) as well as the efficacy and safety of TGC which may have 
had some influence on the outcomes. Furthermore, this study 
included patients with severe sepsis, known to be at a higher risk 
for hypoglycaemia,1 while the Leuven 1 included mainly coronary 
bypass surgery patients. In addition, the fluid resuscitation arm of 
the study was also suspended due to an increased risk of organ 
failure (10%) in the pentastarch arm. This reiterates the point that 
the resuscitation fluid rather than the glucose control may have 
caused the higher mortality.
The VISEP trial, as well as the Glucontrol study,34 was stopped due 
to high rates of hypoglycaemia (12.1/18.6% respectively), but there 
was no difference in mortality. An additional factor for the cessation 
of the Glucontrol study was a high rate of unintentional protocol 
violations.35 It is also possible that the low number of patients per 
centre may have contributed to the lack of treatment effect.5 The 
Glucontrol study was only released in abstract form, thus it is not 
possible to assess methodology fully.
The different outcomes in terms of mortality between the Leuven 
studies27,28 and the two mixed ICU population studies3,32 may possibly 
be explained by the different study designs, populations and the 
age difference in the study populations.3,32 Another aspect that 
may indicate some difference in the study population is the high 
in-hospital mortality (10.9%) in the control group of the Leuven 1 
study.27 A subsequent study to investigate this point found an in-
hospital mortality rate in similar patients in Australia to be only 3.8%, 
much lower than the mortality of both the treatment and control 
groups in the Leuven 1 trial.36
The NICE-SUGAR study and the Leuven 1 and 2 studies are most 
often compared in an effort to come to a conclusion with regards to 
TGC. However, various differences between these studies need to be 
pointed out. The Leuven studies were single centre trials while the 
NICE-SUGAR study was a multicentre trial. The accuracy of measuring 
tools at different centres and the experience of the nursing staff with 
TGC come into play.1,24 Avoiding variable blood glucose and exact 
titration requires experience of the nursing staff1,24 which may have 
been lacking in a multicentre trial.
It was also noted that the control group in the NICE-SUGAR study had 
an average BG of 7.8–10,0 mmol/L while it was 10.0–11.1 mmol/L 
in the Leuven studies.2,27,28,37 This essentially means that the control 
group was already better controlled by targeting an intermediate 
blood glucose level, which makes a direct comparison between 
the studies difficult. It was speculated that the better control in 
the control group might have improved outcomes to such a degree 
that tighter control would not have resulted in a more significant 
benefit.9,24,37 Van Den Berghe, et al (2009) agreed with this conclusion 
and suggested that an intermediate target range may be preferable 
in critically ill patients.24 
In addition, the NICE-SUGAR (MICU and SICU) study is often compared 
to the Leuven 1 study, which was on SICU patients (predominantly 
cardiac surgery) only. In this regard, the NICE-SUGAR study results 
are more similar to that of the two mixed ICU studies.3,32 
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Furthermore, various other differences between the studies may 
have affected outcomes, such as early nutrition support and 
its mode of administration as well as energy content, and BMI 
status.24,37 It is also important to note that some studies already 
described included both diabetic and stress induced hyperglycaemia 
patients, which is unfortunate, since recent data indicates that the 
two settings are different.38 A comparison of outcomes in patients 
with known diabetes to those without diabetes after implementation 
of a moderate glycaemic control protocol (6.9 mmol/L) showed a 
significant reduction in mortality in non-diabetic patients, but not in 
those with known diabetes.39 It is also unfortunate that the diabetic 
sub-sets were presented differently in the Leuven and NICE-SUGAR 
studies (type 1 and 2 versus on insulin or on oral medication/diet) 
making comparisons and conclusions even more difficult.
Other differences between the Van Den Berghe studies and 
subsequent studies, which are not comprehensively described herein, 
include: different target ranges for blood glucose control, differences 
in the definition of hypoglycaemia, duration of hyperglycaemia 
preceding the intervention and varying levels of expertise with the 
therapy among the ICU nurses and a high nurse to patient ratio in 
the Leuven studies,1,9,24,38 APACHE scores, age of patients, the degree 
with which blood glucose levels fluctuated in an individual patient 
as well as quality of the glucose control process itself, the case mix, 
associated therapy (e.g. corticosteroids), the existing variability in 
the intervention evaluation, the timing of the initiation of IIT and the 
variability in outcomes measures.4,9,35,36,40 
Mechanisms of potential beneficial effects of tight 
control
Irrespective of the limitations in comparing the described studies, 
the question still remains whether insulin therapy per se improved 
mortality directly through modulating the inflammatory response 
or indirectly through improving hyperglycaemia, and consequently 
metabolism (Table I).  In this regard, insulin is an anabolic and anti-
catabolic hormone. Insulin is also a regulator of the inflammatory and 
immune responses, which may contribute to the reduced mortality 
after IIT in some studies.41 Furthermore, sub-maximal doses of insulin 
have been shown to enhance skeletal muscle protein anabolism in 
severely burned (> 60% TBSA) patients,42 which may also contribute 
to reduced mortality in certain patients groups.
Hypoglycaemia
The major obstacle with TGC appears to be hypoglycaemia, which 
is possibly the major contributing factor to the poor outcomes 
documented in some studies. It thus appears that in order to benefit 
from TGC, hypoglycaemia needs to be avoided. The mechanism 
by which hypoglycaemia increases mortality in severe sepsis and 
shock has not been fully investigated. One possible mechanism 
is brain damage because of an energy deficit in the brain through 
hypglycaemia.6 Many recent studies have reported significant 
rates of hypoglycaemia with TGC (defined as BG < 2.2 mmo/L). 
The incidence of hypoglycaemia in tight control groups varied from 
7–20% and was as low as 0.5% in control groups in ICU-based 
studies (Table II).23
Juneja et al (2009) found that the most common contributing 
cause for hypoglycaemia was measurement delay.8 It is known that 
severe hypoglycaemia increases stress hormone levels in normal 
individuals, but adequacy of this response in critically ill patients 
with already increased stress hormone levels is not known.23 
Furthermore, the majority of hypoglycaemic episodes has been 
shown to occur during unplanned interruption of feeding.51,52 From 
the Leuven studies it also appears that medical patients might be at 
a higher risk for hypoglycaemia, possibly due to higher necessity for 
treatments known to affect blood glucose control such as inotrope 
support, corticosteroid administration and renal replacement therapy. 
Liver failure and kidney failure, which increase the vulnerability to 
hypoglycaemia, may also partly explain this observation.
Another reason for the higher mortality with TGC may be due to the 
limitations in measuring glucose using the point-of-care devices 
(glucometers), since the glucose concentration obtained by these 
devices differs significantly from those obtained by conventional 
Table I: Possible mechanisms of beneficial effects of insulin
Wade 200843
Hyperglycaemia alters cytokine production and 
phagocytosis
Vanhorebeek et al, 200544
Strict blood glucose control protects hepatocyte 
mitochondrial ultrastructure and function
Herman et al, 200745
Herman et al, 200946
Intensive insulin therapy prevents critical 
polyneuropathy/myopathy
Dugo et al, 200647
Insulin inhibits glycogen synthase kinase-3β, 
contributes to protective effect of insulin against 
organ injury/dysfunction caused by excessive 
systemic inflammation, independent from its effect 
on glucose
Bopp et al, 200848
Tight glycaemic control may decrease AGE 
(advanced glycation end product) formation 
and thereby reduce the inflammatory response 
mediated through AGE and RAGE (receptor of 
advanced glycation end product) interaction
Jeschke et al, 200249
Jeschke et al, 200450
Insulin decreases pro-inflammatory cytokines 
and proteins and increases the anti-inflammatory 
cascade in burned rats and children (BG between 
6.6–10 mmol/lL). 
Table II: Incidence of hypoglycaemia with TGC
STUDY TGC CONTROL
Leuven 127 5.1% 0.8%










De La Rosa et al32 8.5% 1.7%
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laboratory methods.53 In the NICE-SUGAR study only 60.1% 
of the hypoglycaemic episodes were confirmed by laboratory 
measurement.2 A variety of glucometers were allowed in the NICE-
SUGAR study. The accuracy of some types of glucometers has been 
shown to be poor in the ICU setting.54 In addition, many critically ill 
patients are anaemic and it has been shown that a haematocrit of 
< 34% produces systematic errors in glucometer measurements.55 
Moreover, anaemia results in falsely elevated BG levels, while 
polycythaemia results in low values.56  It is interesting in this regard 
that a correction formula has been developed which, when applied to 
device derived glucose concentrations, was associated with a 78% 
decrease in hypoglycaemia in the presence of TGC practices.55 
Hirasawa et al (2009) used a novel approach to indicate “good” and 
“bad” responders to tight glycaemic control.6 An interleukin-6 (IL-6) 
level of 1000 pg/ml can be used to diagnose systemic inflammatory 
response syndrome (SIRS) or hypercytokinaemia. Applying TGC 
(6.6–8.3 mmol/L) to patients with severe sepsis and septic 
shock resulted in a success rate of TGC was only 53%. When the 
researchers divided the patients into subgroups according to 
IL-6 levels on admission to ICU, they found that the success rate 
of TGC was relatively high in those with an IL-6 < 1000 mg/dl on 
admission, but very low in those with a level of > 10000 pg/ml.6 
A protocol prescribing the control process may improve BG control.4 
TGC (4.4–4.6 mmol/L) in ICU patients, by using a computerised 
insulin dosing algorithm, resulted in hypoglycaemia in only 4.25% 
patients with 97.5% achieving target range and remained on target 
73.4% of the time.8 Unfortunately this study was not randomised, 
it was retrospective in nature and employed various BG sampling 
methods. The SPRINT protocol was applied in a general ICU to 
achieve TGC (4.4–6.1mmol/L). The implementation of the SPRINT 
protocol resulted in only 9.0% of all measurements being below 
4.4 mmol/L, 3.8% below 4 mmol/L and 0.1% of measurements 
below 2.2 mmol/L. Hospital mortality was reduced for ≥ 3 (from 
34.1% to 25.4%), ≥ 4 (from 34.3% to 23.5%) and ≥ 5 days (from 
31.9% to 20.6%).7 
Recommendations
Some recent recommendations for BG control targets (Table III) and 
safe recommendations for implementation of TGC (Table IV) are 
presented in the respective Tables.
Conclusion
Hyperglycaemia is associated with adverse effects in the critically 
ill patient. Studies investigating the effect of TGC, unfortunately, to 
date have not provided a definitive answer to the question whether 
TGC will improve mortality. The greatest risk in some studies on 
TGC has been shown to be hypoglycaemia. Future research needs 
to focus on blood glucose target for different populations and the 
design of effective tools to reach the targets safely. Furthermore, a 
distinction should be made between diabetic patients and other ICU 
patients, and the effect of nutrition support protocols and glucose 
variability should be assessed. In the meantime, it would be prudent 
to practice a moderate control target in the ICU, in general, with 
particular attention to settings that contribute to the precipitation of 
hypoglycaemia. 
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